We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.35B
AUM Growth
+$9.88M
Cap. Flow
+$151M
Cap. Flow %
11.19%
Top 10 Hldgs %
48.37%
Holding
65
New
13
Increased
7
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$45.3M
2
AUTL
Autolus Therapeutics
AUTL
+$40.3M
3
KZR
Kezar Life Sciences
KZR
+$27.4M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$26.1M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$22.2M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$81.7M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.7M
3
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$12.7M
4
CLSD
Clearside Biomedical
CLSD
+$7.65M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$7.01M

Sector Composition

Rank Sector Weight
1 Healthcare 88.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$94.9M 7.02%
4,312,498
+224,269
+5% +$5.15M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$94.6M 7%
1,918,350
– –
NKTR icon
3
CALL
Nektar Therapeutics
NKTR
$2.41B
$89.3M 6.61%
121,893
+19,833
+19% +$22.9M
ANAB icon
4
AnaptysBio
ANAB
$1.63B
$87.6M 6.48%
1,233,422
+129,400
+12% +$10.9M
NKTR icon
5
Nektar Therapeutics
NKTR
$2.41B
$73.2M 5.42%
100,000
-70,880
-41% -$81.7M
IFRX icon
6
InflaRx
IFRX
$253M
$48M 3.55%
1,487,265
+88,235
+6% +$3.05M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$44.1M 3.26%
3,600,954
– –
TECX
8
Tectonic Therapeutic
TECX
$538M
$43.1M 3.19%
+125,649
New +$45.3M
AUTL
9
Autolus Therapeutics
AUTL
$407M
$40.9M 3.02%
+1,525,587
New +$40.3M
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$38M 2.81%
767,363
– –
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$37.5M 2.78%
239,619
– –
BPMC
12
DELISTED
Blueprint Medicines
BPMC
$34.9M 2.58%
550,000
+117,937
+27% +$9.39M
QTNT
13
DELISTED
Quotient Limited Ordinary Shares
QTNT
$34.5M 2.55%
107,271
– –
GTHX
14
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$31.3M 2.32%
719,985
– –
RCKT icon
15
Rocket Pharmaceuticals
RCKT
$351M
$29.8M 2.21%
1,519,890
-1
-0% -$19
TBPH icon
16
Theravance Biopharma
TBPH
$873M
$29.5M 2.18%
1,300,000
– –
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
$27.9M 2.07%
+934,588
New +$26.1M
KZR
18
DELISTED
Kezar Life Sciences
KZR
$27.2M 2.01%
+157,291
New +$27.4M
SPPI
19
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$25.2M 1.86%
+1,200,000
New +$22.2M
ASND icon
20
Ascendis Pharma A/S
ASND
$16.5B
$24.7M 1.83%
371,739
– –
TSRO
21
DELISTED
TESARO, Inc.
TSRO
$24.5M 1.81%
550,000
+200,000
+57% +$9.71M
SLDB icon
22
Solid Biosciences
SLDB
$836M
$24.4M 1.81%
45,730
-1
-0% -$308
OMER icon
23
Omeros
OMER
$863M
$23.8M 1.76%
1,314,118
– –
ARGX icon
24
argenx
ARGX
$54.6B
$23.1M 1.71%
278,536
– –
ARNA
25
DELISTED
Arena Pharmaceuticals Inc
ARNA
$19.6M 1.45%
450,000
+325,000
+260% +$14M
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Cormorant Asset Management held 65 positions worth $1.35B, up 0.74% from $1.34B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management deployed $151M of net new capital in Q2 2018, opening 13 new positions and adding to 7 existing holdings. Its largest new stake was Tectonic Therapeutic: 125,649 shares worth $43.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 83% a quarter earlier.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $81.7M trimmed.

  • Cormorant Asset Management's largest Q2 2018 buy was Tectonic Therapeutic: 125,649 shares worth $43.1M.
  • Cormorant Asset Management added most to Arena Pharmaceuticals Inc in Q2 2018, an estimated $14M increase.
  • Cormorant Asset Management's biggest Q2 2018 reduction was Nektar Therapeutics, cutting an estimated $81.7M.
  • Cormorant Asset Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $23.7M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $1.35B portfolio in Q2 2018.
  • Cormorant Asset Management opened 13 new positions and closed 7 in Q2 2018.
  • Cormorant Asset Management's portfolio value rose 0.74% quarter-over-quarter to $1.35B.

Based on Cormorant Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.